TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

Search

CSL Ltd

Suletud

SektorTööstus

255.36 1.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

250.4

Max

256

Põhinäitajad

By Trading Economics

Sissetulek

1.3B

2B

Müük

1.5B

8.2B

P/E

Sektori keskmine

28.972

35.58

Aktsiakasum

1.831

Dividenditootlus

1.7

Kasumimarginaal

24.437

Töötajad

32,698

EBITDA

1.5B

3.2B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+27.2% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.70%

2.64%

Järgmine dividendimakse kuupäev

9. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-14B

121B

Eelmine avamishind

253.47

Eelmine sulgemishind

255.36

Uudiste sentiment

By Acuity

50%

50%

207 / 468 Pingereas Industrials

CSL Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2025, 21:55 UTC

Tulu

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. veebr 2025, 21:34 UTC

Tulu

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12. aug 2024, 23:23 UTC

Tulu

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12. aug 2024, 22:49 UTC

Tulu

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21. märts 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11. veebr 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10. veebr 2025, 21:40 UTC

Tulu

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. veebr 2025, 21:19 UTC

Tulu

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10. veebr 2025, 21:13 UTC

Tulu

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10. veebr 2025, 21:12 UTC

Tulu

CSL Interim Dividend US$1.30/Security

10. veebr 2025, 21:12 UTC

Tulu

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10. veebr 2025, 21:11 UTC

Tulu

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7. nov 2024, 03:53 UTC

Market Talk

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22. okt 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10. okt 2024, 22:20 UTC

Market Talk

CSL Bull Looking for Update on Gross Margin -- Market Talk

13. aug 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12. aug 2024, 22:34 UTC

Tulu

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12. aug 2024, 22:18 UTC

Tulu

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12. aug 2024, 22:18 UTC

Tulu

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12. aug 2024, 22:17 UTC

Tulu

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12. aug 2024, 22:16 UTC

Tulu

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12. aug 2024, 22:15 UTC

Tulu

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12. aug 2024, 22:14 UTC

Tulu

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12. aug 2024, 22:13 UTC

Tulu

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12. aug 2024, 22:13 UTC

Tulu

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12. aug 2024, 22:11 UTC

Tulu

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12. aug 2024, 22:10 UTC

Tulu

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12. aug 2024, 22:09 UTC

Tulu

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12. aug 2024, 22:08 UTC

Tulu

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12. aug 2024, 22:07 UTC

Tulu

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Võrdlus sarnastega

Hinnamuutus

CSL Ltd Prognoos

Hinnasiht

By TipRanks

27.2% tõus

12 kuu keskmine prognoos

Keskmine 317.093 AUD  27.2%

Kõrge 360.3 AUD

Madal 250 AUD

Põhineb 14 Wall Streeti analüütiku instrumendi CSL Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

12

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

207 / 468 Pingereas Tööstus

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.